Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

作者：Bryan D. Choi, Elizabeth R. Gerstner, Matthew J. Frigault, Mark B. Leick, Christopher Mount, Leonora Balaj, Sarah Nikiforow, Bob S. Carter, William T. Curry, Kathleen Gallagher, Marcela V. Maus · 发表于：New England Journal of Medicine · 年份：2024 · DOI：10.1056/nejmoa2314390 · 被引用次数：443 · 研究领域：CAR-T cell therapy research、Advancements in Semiconductor Devices and Circuit Design、Nanowire Synthesis and Applications

In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).